复发甲状腺髓样癌中68Ga-FAPI-04与68Ga-DOTA-TATE PET/CT的头对头比较
纳入16例降钙素>150 pg/mL的复发甲状腺髓样癌患者行FAPI与SSTR PET/CT。患者分析SSTR灵敏度更高(88% vs 81%,P=0.004);病灶分析FAPI在颈部淋巴结、纵隔淋巴结和肝转移准确率更高。31%患者FAP表达肝病灶SSTR无摄取,其中2例证实为血管瘤。
要点
- 患者分析SSTR灵敏度88% vs FAPI 81%,差异有统计学意义(P=0.004)。
- 病灶分析FAPI在颈部淋巴结(91.9% vs 50%)、纵隔淋巴结(94.9% vs 54.4%)和肝转移(57.4% vs 7.3%)准确率高于SSTR。
- 31%患者(n=5)FAP表达肝病灶SSTR无摄取,MRI证实3例肝转移、2例血管瘤。
核心结论
- FAPI PET在复发MTC患者转移灶检测中呈现有前景的结果。
- FAPI诊断性能在患者分析层面与SSTR相当,在病灶分析层面对肝和骨转移的灵敏度和准确率更优。
研究设计与样本
- 16例降钙素>150 pg/mL的复发MTC患者行FAPI与SSTR PET/CT。
- 两名核医学医师评估所有图像,将病灶分类为局部区域转移、纵隔淋巴结、肝和骨转移,记录SUVmax与靶本比。
- PET方法比较采用McNemar检验,计算FAPI与SSTR PET的灵敏度、特异度、阳性预测值、阴性预测值和准确率。
主要发现
- 队列16例患者(50%女性;平均年龄50±17岁),降钙素和CEA中位数分别为6234 pg/mL和17.3 ng/mL。
- 患者分析SSTR灵敏度88% vs FAPI 81%,差异有统计学意义(P=0.004)。
- 平均SUVmax和靶本比:FAPI为10.3和5.35,SSTR PET为9.7和11.9。
- 病灶分析FAPI准确率高于SSTR:颈部淋巴结91.9% vs 50%,纵隔淋巴结94.9% vs 54.4%,肝转移57.4% vs 7.3%。
- 31%患者(n=5)FAP表达肝病灶SSTR无摄取,MRI证实其中3例肝转移、2例血管瘤;DOTA假阳性主要为反应性淋巴结和骨血管瘤。
关键数值与推荐
- 患者分析SSTR灵敏度88% vs FAPI 81%,P=0.004。
- 病灶分析准确率:颈部淋巴结FAPI 91.9% vs SSTR 50%,纵隔淋巴结94.9% vs 54.4%,肝转移57.4% vs 7.3%。
- 平均SUVmax:FAPI 10.3 vs SSTR 9.7;平均靶本比:FAPI 5.35 vs SSTR 11.9。
- 降钙素和CEA中位数分别为6234 pg/mL和17.3 ng/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to compare the diagnostic performance of 68Ga-FAPI-04 (FAPI) in comparison to 68Ga-DOTATATE (SSTR) PET/CT for patients presenting with recurrent medullary thyroid carcinoma (MTC). PATIENTS AND METHODS: Sixteen MTC patients with elevated calcitonin levels (>150 pg/mL) underwent FAPI and SSTR PET/CT. Two nuclear medicine physicians evaluated all images, categorizing lesions into locoregional metastases, mediastinal lymph nodes (LNs), liver, and bone metastases. SUVmax and tumor-to-background ratio were recorded. PET modalities were compared using the McNemar test. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of FAPI and SSTR PET were calculated. RESULTS: The cohort comprised 16 patients (50% female; mean age 50 ± 17 years). Median calcitonin and CEA levels were 6234 pg/mL and 17.3 ng/mL, respectively. In patient-based analysis, SSTR exhibited higher diagnostic sensitivity compared with FAPI (88% vs 81%), resulting a statistically significant difference (P = 0.004). Mean SUVmax and tumor-to-background ratio values were 10.3 and 5.35 for FAPI, and 9.7 and 11.9 for SSTR PET, respectively. In lesion-based analyses, FAPI demonstrated higher accuracy than SSTR for cervical LNs (91.9% vs 50%), mediastinal LNs (94.9% vs 54.4%), and liver metastases (57.4% vs 7.3%), respectively. Notably, 31% of patients (n = 5) with FAP-expressing liver lesions showed no uptake on SSTR imaging. MRI confirmed liver metastases in 3 of these patients; however, 2 FAP-expressing lesions were confirmed as hemangiomas. False-positive findings of DOTA primarily included reactive LNs and bone hemangiomas. CONCLUSIONS: FAPI PET presents promising outcomes in detecting metastases in recurrent MTC patients. Although its diagnostic performance matches SSTR on a per-patient basis, FAPI PET exhibits superior sensitivity and accuracy in lesion-based analyses, notably for liver and bone metastases.
引用
- Isik EG, Has Simsek D, Gul N, et al. Head-to-Head Comparison of 68Ga-FAPI-04 and 68Ga-DOTA-TATE PET/CT in Recurrent Medullary Thyroid Cancer. Clin Nucl Med. 2024. PMID: 39774244. doi:10.1097/RLU.0000000000005558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。